搜索公司,投資者……

Hatteras投資夥伴

hatterasinvestmentpartners.com

關於Hatteras投資夥伴

Hatteras投資夥伴創建performance-focused另類投資幫助顧問建立更好的投資組合的解決方案。

總部的位置

羅利北卡羅萊納27615年,

美國

919-846-2324

188bet游戏
尋找一個腿上有競爭力的,客戶技術見解?
188bet游戏CB的見解將信心和清晰你最戰略決策。
看看。加入一個演示。
加入一個演示
信任由世界最聰明的公司:
  • 預測新興趨勢
  • 看到競爭對手的劇本
  • 莖精明的投資者
  • 確定明天的挑戰者
  • 現貨產業增長
  • 殺了分析師的數據工作
讓我們看看我們如何能幫助你!
微軟 沃爾瑪 富國銀行(Wells Fargo)
你一次點擊從最全麵、無與倫比的分析師專長技術,深入的私人公司數據和一個平台,將它們放在一起。
現在點擊。加入一個現場演示
加入一個演示

最新的Hatteras投資夥伴新聞

髓治療:臨床階段mRNA-Immunotherapy公司油墨7300萬美元的資金

2023年6月4日,

髓治療,臨床分期mRNA-immunotherapy公司——宣布完成了7300萬美元的資金由Hatteras新投資者的投資合作夥伴參與拱Venture Partners和摩爾的戰略投資。所有現有的投資者,包括Newpath夥伴,8風險投資,風險投資,和亞曆山大也參加了。所得資金將支持繼續mt - 101的臨床發展,骨髓的細胞療法項目階段1/2 T細胞淋巴瘤,並將加快發展mt - 302,一個first-in-class TROP2-FcA mRNA-LNP產品,為TROP2-expressing腫瘤1/2研究階段。和額外的體內編程候選人也推進診所。mt - 302:從公司的專有ATAK汽車受體圖書館,骨髓的小說體內工程平台具體目標和激活骨髓細胞引起更廣泛的抗腫瘤獲得性免疫。通過這種方法,骨髓表明交付lipid-nanoparticles (lnp)封裝mRNA的結果由髓細胞體內吸收和選擇性表達,導致有效的腫瘤死亡在多個冷腫瘤模型。公司的領導體內程序mt - 302是一個TROP2-targeting體內骨髓內艙車專為表達式。和TROP2腫瘤相關抗原表達廣泛上皮腫瘤,包括一些最難治性癌症。mt - 302表明單一療法治療活動TROP2 / TNBC模型,確定程序的效力髓細胞在T細胞的缺失。骨髓相信mt - 302 TROP2-ADC方法相比有明顯優勢通過其進行完整的免疫反應的能力。 In 2023, Myeloid expects to initiate a Phase 1/2 clinical study with MT-302 for patients with TROP2-expressing tumors. MT-101: MT-101 is the company’s first autologous CAR monocyte. And this candidate was derived from the Company’s proprietary ATAK platform and designed to harness the ability of myeloid cells to penetrate into tumors and promote broad anti-tumor activity. Plus MT-101 targets CD5, a surface receptor that is present in greater than 75% of peripheral T cell lymphomas. To create MT-101, the patient’s cells are engineered ex vivo with the mRNA-strand coding for the CAR. The engineered cells are delivered back to the patient within a vein-to-vein time of eight days. The ATAK CAR is proprietary to Myeloid and manufactured using the Company’s patented processes. The IMAGINE study (NCT05138458) is a Phase 1/2, multicenter, open-label, first-in-human, multiple ascending dose study to evaluate MT-101 in patients with refractory or relapsed PTCL and CTCL. The dose-escalation portion of this study, conducted with and without conditioning therapy, is open and enrolling patients. RetroT: Retrotransposons are genetic elements that replicate through reverse transcription of an RNA transposition intermediate. And retrotransposons contribute to structural changes and more importantly, to gene regulation. Myeloid’s RetroT technology relies on a single-strand mRNA to deliver genetic sequences and integration enzymes. This breakthrough technology offers the potential to deliver gene-sized pieces of DNA into the genome in a virus-free manner. And the payload realizable with RetroT is larger than currently possible with all known existing gene editing technologies. As a result, the company’s RetroT platform holds the potential to significantly expand the type and scope of genetic errors that can be reversed in situ. In March 2022, Myeloid entered into an exclusive option and research collaboration agreement with Prime Medicine to develop and accelerate RetroT. KEY QUOTES: “Myeloid continues to make significant progress across all aspects of our business. We are pioneering the convergence of immunology and RNA science to build a clinical-stage portfolio of products, starting with the significant unmet needs of cancer patients. We are pleased that such high-quality investors have joined with us to accelerate this effort.” — Daniel Getts, Ph.D., Chief Executive Officer of Myeloid “Hatteras focuses on investments in cutting-edge companies that are disrupting the status quo and accelerating the pace of innovation. We are highly encouraged by the innovation, execution and clinical development progress demonstrated by Myeloid. We are proud to support this field-leading Company through its next phase of growth and are optimistic that these approaches will drive a meaningful clinical outcome for patients.” — Clay B. Thorp, General Partner at Hatteras Trending on Pulse 2.0

Hatteras投資夥伴常見問題(FAQ)

  • Hatteras投資夥伴的總部在哪裏?

    Hatteras投資夥伴的總部位於羅利。

188bet游戏
尋找一個腿上有競爭力的,客戶技術見解?
188bet游戏CB的見解將信心和清晰你最戰略決策。
看看。加入一個演示。
加入一個演示
信任由世界最聰明的公司:
  • 預測新興趨勢
  • 看到競爭對手的劇本
  • 莖精明的投資者
  • 確定明天的挑戰者
  • 現貨產業增長
  • 殺了分析師的數據工作
讓我們看看我們如何能幫助你!
微軟 沃爾瑪 富國銀行(Wells Fargo)

發現正確的解決方案為您的團隊

CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。

加入一個演示

CBI的網站通常使用一些餅幹,使更好的相互作用我們的網站和服務。使用這些餅幹,這可能是存儲在你的設備上,允許我們的改進和定製你的經曆。你可以閱讀更多關於你的餅幹的選擇在我們的隱私政策在這裏。繼續使用這個你同意這些選擇。

Baidu
map